9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
{{output}}
Backgroud: A first-in-human study was performed to assess the safety and preliminary antitumor activity of 9MW2821, a next-generation monoclonal antibody-drug conjugate (ADC) that delivers monomethylauristatin E (MMAE) to cells e... ...
